| Dr George Chiarchiaro, DDS | |
|
1631 E. Highway 66, El Reno, OK 73036 | |
| (405) 262-7631 | |
| (405) 262-8099 |
| Full Name | Dr George Chiarchiaro |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 1631 E. Highway 66, El Reno, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114070331 | NPI | - | NPPES |
| 1307831 | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 07831 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr George Chiarchiaro, DDS 3625 Nw 56th St, Oklahoma City, OK 73112-4519 Ph: (405) 951-3818 | Dr George Chiarchiaro, DDS 1631 E. Highway 66, El Reno, OK 73036 Ph: (405) 262-7631 |
News Archive
Pharmaceutical company Novartis "has spoken out following criticism about its challenge to India's patent laws, insisting that access to life-saving drugs is not under peril by the move," Pharma Times World News reports. The case, which the Indian Supreme Court is scheduled to hear next month, challenges "Indian patent law, notably Section 3(d), which states that a modification of a known chemical composition is non-patentable," the news service writes.
Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
The effort to fix our dysfunctional, inequitable and unsustainable health system is at a crucial juncture. Without prompt and decisive leadership, defeat, as it has for over a century, will again prevail over reform.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
› Verified 6 days ago
Dr. Emily Bourke, DDS Dentist Medicare: Medicare Enrolled Practice Location: 1801 Parkview Dr, El Reno, OK 73036 Phone: 405-295-1500 | |
Dr. Cristina Lynn Brovont, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 1631 E Us Highway 66, Suite A, El Reno, OK 73036 Phone: 405-422-8434 | |
Christinna Renee Fairchild, DDS Dentist Medicare: Medicare Enrolled Practice Location: 2005 Parkview Dr, Suite 2, El Reno, OK 73036 Phone: 405-262-1919 Fax: 405-262-1974 | |
Daniel W Brockmeier, DMD Dentist Medicare: Medicare Enrolled Practice Location: 1631 A East Hwy 66, El Reno, OK 73036 Phone: 405-262-7631 Fax: 405-262-8099 | |
Dr. Michael Compton, D.D.S. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1320 W Elm St, El Reno, OK 73036 Phone: 405-262-6737 Fax: 405-262-6738 | |
Dr. Robin Elaine White, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 1705 W Elm St, El Reno, OK 73036 Phone: 405-262-2289 Fax: 405-262-2292 |